Lv3
280 积分 2023-02-27 加入
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
2个月前
已完结
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
2个月前
已关闭
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
2个月前
已关闭
Statistical Quality and Process Control in Biopharmaceutical Manufacturing—Practical Issues and Remedies
4个月前
已完结
Bimekizumab versus Adalimumab in Plaque Psoriasis
4个月前
已完结
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis
4个月前
已完结
Bimekizumab versus Secukinumab in Plaque Psoriasis
4个月前
已完结
Bimekizumab versus Adalimumab in Plaque Psoriasis
5个月前
已完结
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
6个月前
已完结
Surface Charge and Solvent Exposure Dictate the pH-Dependent Viscosity of Therapeutic Antibodies
7个月前
已完结
皖公网安备34019202002308
